From January 1, 2024 to March 31, 2024, the company has repurchased 409,700 shares, representing 0.1% for CNY 5.13 million. With this, the company has completed the repurchase of 1,161,200 shares, representing 0.29% for CNY 15.39 million under the buyback announced on November 16, 2023.
Shanghai Labway Clinical Laboratory Co., Ltd
Equities
301060
CNE100004RG8
Healthcare Facilities & Services
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.42 CNY | +1.36% | -3.34% | -21.60% |
1st Jan change | Capi. | |
---|---|---|
-21.60% | 577M | |
-16.99% | 8.55B | |
+65.23% | 4.24B | |
-1.63% | 2.54B | |
-41.76% | 2.35B | |
-8.53% | 1.89B | |
-19.29% | 1.55B | |
-39.61% | 1.23B | |
+9.54% | 1.13B | |
+19.57% | 955M |
- Stock Market
- Equities
- 301060 Stock
- News Shanghai Labway Clinical Laboratory Co., Ltd
- Tranche Update on Shanghai Labway Clinical Laboratory Co., Ltd's Equity Buyback Plan announced on November 16, 2023.